ITs were selected basing on three considerations: (i) TfR1, EGFR1 and Her2 antigens have been well exploited as targets for cancer immunotherapy in several carcinoma models [15,16,17,18]; (ii) the overexpression of these antigens was reported in primary or advanced sarcoma [6,7,8]; (iii) ITs directed against those antigens were previously evaluated in some carcinoma and sarcoma cell lines, showing high cytotoxicity [19,20,21]. The gene discussed is TFRC; the disease is cancer.